432 related articles for article (PubMed ID: 27393904)
1. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
[TBL] [Abstract][Full Text] [Related]
2. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.
Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C
BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.
Thomson E; Ip CL; Badhan A; Christiansen MT; Adamson W; Ansari MA; Bibby D; Breuer J; Brown A; Bowden R; Bryant J; Bonsall D; Da Silva Filipe A; Hinds C; Hudson E; Klenerman P; Lythgow K; Mbisa JL; McLauchlan J; Myers R; Piazza P; Roy S; Trebes A; Sreenu VB; Witteveldt J; ; Barnes E; Simmonds P
J Clin Microbiol; 2016 Oct; 54(10):2470-84. PubMed ID: 27385709
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay.
Manee N; Thongbaiphet N; Pasomsub E; Chantratita W
J Virol Methods; 2017 Nov; 249():31-37. PubMed ID: 28851606
[TBL] [Abstract][Full Text] [Related]
5. Performance assessment of a fully automated deep sequencing platform for HCV resistance testing.
Rodriguez C; Mercier-Darty M; Soulier A; Poiteau L; Wlassow M; Fourati S; Hézode C; Pawlotsky JM; Chevaliez S
Antivir Ther; 2019; 24(6):417-423. PubMed ID: 31112134
[TBL] [Abstract][Full Text] [Related]
6. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
[TBL] [Abstract][Full Text] [Related]
7. Full-genome next-generation sequencing of hepatitis C virus to assess the accuracy of genotyping by the commercial assay LiPA and the prevalence of resistance-associated substitutions in a Belgian cohort.
Christensen KT; Pierard F; Beuselinck K; Bonsall D; Bowden R; Lagrou K; Nevens F; Schrooten Y; Simmonds P; Vandamme AM; Van Wijngaerden E; Dierckx T; Cuypers L; Van Laethem K
J Clin Virol; 2022 Oct; 155():105252. PubMed ID: 35981443
[TBL] [Abstract][Full Text] [Related]
8. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
[TBL] [Abstract][Full Text] [Related]
9. HCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasma.
Qiu P; Stevens R; Wei B; Lahser F; Howe AY; Klappenbach JA; Marton MJ
PLoS One; 2015; 10(4):e0122082. PubMed ID: 25830316
[TBL] [Abstract][Full Text] [Related]
10. Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols.
Caputo V; Diotti RA; Boeri E; Hasson H; Sampaolo M; Criscuolo E; Bagaglio S; Messina E; Uberti-Foppa C; Castelli M; Burioni R; Mancini N; Clementi M; Clementi N
Virol J; 2020 Jul; 17(1):103. PubMed ID: 32660499
[TBL] [Abstract][Full Text] [Related]
11. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O
Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684
[TBL] [Abstract][Full Text] [Related]
12. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy.
Peng P; Xu Y; Fried MW; Di Bisceglie AM; Fan X
BMC Infect Dis; 2020 Aug; 20(1):632. PubMed ID: 32847527
[TBL] [Abstract][Full Text] [Related]
14. Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.
Barnard R; Chopra A; James I; Blinco J; Watson MW; Jabara CB; Hazuda D; Lemon SM; Mallal S; Gaudieri S
Antivir Ther; 2016; 21(7):567-577. PubMed ID: 27219495
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing.
Bergfors A; Leenheer D; Bergqvist A; Ameur A; Lennerstrand J
Antiviral Res; 2016 Feb; 126():81-9. PubMed ID: 26707078
[TBL] [Abstract][Full Text] [Related]
17. A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing.
Walker A; Bergmann M; Camdereli J; Kaiser R; Lübke N; Timm J
J Clin Virol; 2017 Jun; 91():42-48. PubMed ID: 28463753
[TBL] [Abstract][Full Text] [Related]
18. A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections.
Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM
Infect Genet Evol; 2019 Apr; 69():76-84. PubMed ID: 30654177
[TBL] [Abstract][Full Text] [Related]
19. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.
Di Maio VC; Cento V; Di Paolo D; Aragri M; De Leonardis F; Tontodonati M; Micheli V; Bellocchi MC; Antonucci FP; Bertoli A; Lenci I; Milana M; Gianserra L; Melis M; Di Biagio A; Sarrecchia C; Sarmati L; Landonio S; Francioso S; Lambiase L; Nicolini LA; Marenco S; Nosotti L; Giannelli V; Siciliano M; Romagnoli D; Pellicelli A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Taliani G; Mastroianni C; Vespasiani-Gentilucci U; Romano M; Morisco F; Gasbarrini A; Vullo V; Bruno S; Baiguera C; Pasquazzi C; Tisone G; Picciotto A; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F;
J Antimicrob Chemother; 2016 Mar; 71(3):739-50. PubMed ID: 26679249
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
